Andreas E. Kremer - Concepedia

Author

Andreas E. Kremer

Friedrich-Alexander-Universität Erlangen-Nürnberg ORCID

Also Known As

A E Kremer, A E. Kremer, A Kremer, A. E Kremer, A. E. Kremer, A. Kremer, A.E. Kremer, Andreas E. Kremer, Andreas E Kremer, Andreas E. Kremer

383

Publications

9.5K

Citations

H-Index

135

Concepts

All Affiliations

Friedrich-Alexander-Universität Erlangen-Nürnberg Universitätsklinikum Erlangen University Hospital of Zurich Amsterdam UMC Location University of Amsterdam Newcastle University

About

Andreas E. Kremer is an author at Friedrich-Alexander-Universität Erlangen-Nürnberg specializing in medicine, hepatology, and cholangiopathies.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	32	3.6K
2	Health Sciences	7	7	379
3	Biochemistry	3	3	130
4	Natural Sciences	2	2	168
5	Allergy	1	1	54

Andreas E. Kremer

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Vascular occlusion by neutrophil extracellular traps in COVID-19 Moritz Leppkes, Jasmin Knopf, Elisabeth Naschberger, EBioMedicine	2020	469
Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus Andreas E. Kremer, Job J.W.W. Martens, Wim Kulik, Gastroenterology Animal PhysiologyOxysterolMedicinePhysiologyLysophosphatidic Acid	2010	399
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions Andreas E. Kremer, Remco van Dijk, Pamela Leckie, Hepatology	2012	283
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases David Simón, Koray Taşçılar, Filippo Fagni, Annals of the Rheumatic Diseases	2021	195
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis Gideon M. Hirschfield, Christopher L. Bowlus, Marlyn J. Mayo, New England Journal of Medicine	2024	192
PU.1 controls fibroblast polarization and tissue fibrosis Thomas Wohlfahrt, Simon Rauber, Steffen Uebe, Nature FibrosisMedicinePathologyFibroblast Growth FactorPulmonary Fibrosis	2019	184
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study David Jones, Pol Boudes, Mark G. Swain, The Lancet. Gastroenterology & hepatology Molecular PharmacologySelective Ppar-δ AgonistHepatologyBiliary TractMedicine	2017	181
Fibroblast growth factor 21 is induced by endoplasmic reticulum stress Frank G. Schaap, Andreas E. Kremer, Wouter H. Lamers, Biochimie FibrosisDevelopmental BiologyFibroblast Growth FactorCell ProliferationEndoplasmic Reticulum Stress	2012	157
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis Claudia Günther, Gui-Wei He, Andreas E. Kremer, Journal of Clinical Investigation ImmunologyImmune RegulationPathologyCell DeathInnate Immunity	2016	153

Page 1